Alnylam Pharmaceuticals. has filed a patent for RNAi agents targeting the complement factor B (CFB) gene to treat CFB-associated diseases. The patent claims a specific dsRNA structure for inhibiting CFB expression in cells. GlobalData’s report on Alnylam Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Alnylam Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alnylam Pharmaceuticals, siRNA gene silencing was a key innovation area identified from patents. Alnylam Pharmaceuticals's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Rnai agents targeting complement factor b gene

Source: United States Patent and Trademark Office (USPTO). Credit: Alnylam Pharmaceuticals Inc

The patent application US20240018515A1 discloses a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of complement factor B (CFB) in cells. The dsRNA consists of a sense strand and an antisense strand forming a double-stranded region, with specific nucleotide sequences that target the mRNA encoding CFB. The dsRNA can contain nucleotide modifications, such as deoxy-nucleotide modifications or 2'-O-methyl nucleotide modifications, to enhance its efficacy.

Furthermore, the patent application describes the use of the dsRNA agent in various applications, including as an isolated cell containing the dsRNA agent, a pharmaceutical composition for inhibiting CFB gene expression, and methods for inhibiting CFB gene expression in vitro and treating disorders associated with CFB expression in subjects. The dsRNA agent can also be conjugated to ligands like N-acetylgalactosamine (GalNAc) derivatives for targeted delivery. Overall, the invention provides a novel approach to modulating CFB expression, potentially offering new therapeutic strategies for CFB-associated disorders.

To know more about GlobalData’s detailed insights on Alnylam Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies